Clinical Takeaway
Trauma-focused treatments remain effective for PTSD even when patients report cannabis use alongside co-occurring substance use disorders. Cannabis use does not appear to undermine the clinical benefit of evidence-based, trauma-focused psychotherapy in this population.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical treatment gap by examining whether gold-standard trauma-focused PTSD interventions remain effective in the substantial proportion of patients with concurrent cannabis use and other substance disorders, a population often excluded from efficacy trials. The findings clarify whether clinicians should modify evidence-based PTSD protocols for cannabis-using patients or maintain standard treatment approaches, thereby informing practice guidelines for this high-burden, comorbid population. Understanding treatment efficacy across cannabis use strata is essential for optimizing outcomes in real-world clinical settings where PTSD and polysubstance use frequently co-occur.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis examining trauma-focused treatment outcomes in patients with comorbid PTSD and substance use disorders who also use cannabis addresses a clinically relevant gap, yet several important limitations warrant careful interpretation. The analysis draws from only four of thirty-six available RCTs, which raises questions about generalizability and whether cannabis users may have differed systematically from the broader trial populations in ways that affect treatment response. We lack clarity on cannabis frequency, potency, route of administration, and temporal relationship to treatment, all of which could meaningfully influence outcomes—heterogeneity that meta-analyses often obscure. Additionally, the bidirectional relationship between cannabis use and both PTSD and SUD recovery remains incompletely understood, making it difficult to distinguish whether cannabis impairs treatment efficacy or whether treatment-resistant patients are simply more likely to continue use. Clinically, while we await more definitive evidence, trauma-focused treatments remain our gold standard for comorbid PTSD+SUD, and cannabis use alone should not